Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04064060 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
A Phase 3 study of Beta-Thalassemia and Myelodysplastic Syndromes (MDS), sponsored by Celgene.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 665
- Enrollment target
- 20
- Study locations
NCT04064060: Recruiting Phase 3 study of Beta-Thalassemia and Myelodysplastic Syndromes (MDS), sponsored by Celgene.
NCT04064060 is a Phase 3 study of Beta-Thalassemia and Myelodysplastic Syndromes (MDS) that is actively recruiting participants, run by Celgene. The registered enrollment target is 665 participants, above the 133-participant average among 14 other Beta-Thalassemia trials with a reported enrollment target (400% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04064060, a Phase 3 study of Beta-Thalassemia and Myelodysplastic Syndromes (MDS), is actively recruiting participants, sponsored by Celgene.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 665 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants: * Participants receiving luspatercept on a parent protocol at the time of their transition to the rollover study, who tolerate the protocol-prescribed regimen in the parent trial and, in the opinion of the investigator, may derive clinical benefit from continuing treatment with luspatercept * Participants in the follow-up phase previously treated with luspatercept or placebo in the parent protocol will continue into long-term post-treatment follow-up in the rollover study until the follow-up commitments are met * The study design is divided into the Transition Phase, Treatment Phase and Follow-up Phase. Participants will enter transition phase and depending on their background will enter either the treatment phase or the Long-term Post-treatment Follow-up (LTPTFU) phase * Transition Phase is defined as one Enrollment visit * Treatment Phase: For participants in luspatercept treatment the dose and schedule of luspatercept in this study will be the same as the last dose and schedule in the parent luspatercept study. This does not apply to participants that are in long-term follow-up from the parent protocol * Follow-up Phase includes: \- 42 Day Safety Follow-up Visit * During the Safety Follow up, the participants will be followed for 42 days after the last dose of luspatercept, for the assessment of safety-related parameters and adverse event (AE) reporting \- Long-term Post-treatment Follow-up (LTPTFU) Phase * Participants will be followed for overall survival every 6 months for at least 5 years from first dose of luspatercept in the parent protocol, or 3 years of post-treatment from last dose, whichever occurs later, or until death, withdrawal of consent, study termination, or until a subject is lost to follow-up. Participants will also be monitored for progression to AML or any malignancies/pre-malignancies. New anticancer or d
Primary Outcome
Type, frequency, severity of AEs, relationship of treatment emergent adverse events to luspatercept
Conditions Studied
Interventions
- DRUG Luspatercept
Study Locations (20)
Other
- Royal Prince Alfred Hospital - Camperdown
- Local Institution - 182 - Brasschaat
- Local Institution - 180 - Bruges
- Local Institution - 183 - Ghent
- Local Institution - 184 - Leuven
California
- Childrens Hospital Los Angeles RHU - Los Angeles
- Local Institution - 971 - Oakland
- Local Institution - 978 - Stanford
Florida
- Local Institution - 975 - Tampa
Illinois
- Local Institution - 970 - Chicago
Massachusetts
- Local Institution - 973 - Boston
Michigan
- Local Institution - 961 - Detroit
New York
- Local Institution - 969 - New York
Ohio
- Local Institution - 967 - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 665 participants |
| Start Date | 2019-08-12 |
| Est. Completion | 2028-05-12 |
| Phase | Phase 3 |
What NCT04064060 shows while recruiting
NCT04064060 is an interventional study that assigns participants to a tested intervention. The registered 665 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 14 other Beta-Thalassemia trials with a reported enrollment target (400% higher).
The record links to 3 conditions, with Beta-Thalassemia appearing as the primary indexed condition, and to 1 intervention - of which Luspatercept is the first listed.
NCT04064060 names 20 study sites across 14 states, led by Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT04064060 about?
NCT04064060 is a clinical study titled "A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials". A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants: * Participants receiving luspatercept on a parent protocol at the time of their transition to the rollover study, who tolerate the protocol-prescribed regimen in the p...
What is the current status of trial NCT04064060?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 665 participants. The study started on 2019-08-12. Estimated completion is 2028-05-12.
What conditions does trial NCT04064060 study?
This clinical trial studies the following conditions: Beta-Thalassemia, Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis.
What interventions are being tested in trial NCT04064060?
The interventions under investigation include: Luspatercept (DRUG).
Who is sponsoring clinical trial NCT04064060?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04064060 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Beta-Thalassemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04064060's enrollment target sits among peer trials
665 2nd of 14 the highest of 14 other Beta-Thalassemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Beta-Thalassemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
RECRUITING · Phase 3
-
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
ACTIVE NOT RECRUITING · Phase 3
-
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia
COMPLETED · Phase 3
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
-
A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
RECRUITING
-
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06328647 · 666 participants · NA
Quantra Point-of-Care Hemostasis Monitoring
- NCT06981078 · 666 participants · Phase 2
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
- NCT06607341 · 664 participants · NA
Community Engagement Alliance Against Disparities
- NCT07164443 · 663 participants · Phase 3
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI